| Sep 30 |
INmune Bio Inc. Completes Enrollment for Phase 2 Trial in Early Alzheimer's Disease
|
| Sep 30 |
INmune Bio: NK Cell Therapy INKmune For mCRPC Is Another Shot On Goal
|
| Sep 27 |
Achieve, INmune, Lenz gain on bullish initiations from Raymond James
|
| Sep 17 |
INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints
|
| Sep 13 |
INmune Bio stock dips on $13M securities offering
|
| Sep 13 |
INmune Bio Announces $13.0 Million Registered Direct Offering
|
| Sep 13 |
INmune Bio, Inc.'s (NASDAQ:INMB) top owners are individual investors with 44% stake, while 23% is held by institutions
|
| Aug 2 |
INmune Bio, Inc. (INMB) Q2 2024 Earnings Call Transcript
|
| Aug 1 |
INmune Bio GAAP EPS of -$0.50 beats by $0.13
|
| Aug 1 |
INmune Bio Inc. Announces Second Quarter 2024 Results and Provides Business Update
|
